Products & Innovation / Clinical Trials
The ReSPECT™ clinical trials.
The ReSPECT™ program is evaluating REYOBIQ™ (rhenium Re 186 obisbemeda), an investigational targeted radiotherapy, in three clinical trials across recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.
Considering a trial? Start here.
Clinical trials can be one path worth understanding, and whether one is right for you is a decision for you and your care team. To see which ReSPECT™ trials are enrolling, check eligibility, and find a participating site, visit the ReSPECT™ trials site.
Is your patient a candidate?
REYOBIQ™ is investigational and administered directly to the disease site, by convection-enhanced delivery into the tumor or into the cerebrospinal fluid through an Ommaya reservoir, depending on the indication.
Clinical rationale by indication.
Why locoregional delivery is being studied where systemic therapy is limited by the blood-brain barrier.
Eligibility at a glance.
Phase, enrollment status, and key inclusion and exclusion criteria for ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC.
Participating sites.
Enrolling centers by trial, with current status.
How referral works.
What to send, who receives it, and what happens after a patient is referred.
Protocols and published data.
Protocol summaries, plus Phase 1 results and congress presentations to date.
Following the science.
The ReSPECT™ Programs’ findings are shared as they’re published and presented. Phase 1 REYOBIQ™ results in recurrent glioblastoma were published in Nature Communications, and ReSPECT-LM data have been presented at the SNO Annual Conference.